The Role of Immunotherapy in Hematological Malignancies Volume II

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 15 December 2024 | Viewed by 2433

Special Issue Editor


E-Mail Website
Guest Editor
Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy
Interests: tumor immunotherapy; multiple myeloma pathogenesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This collection is the second edition of the previous one “The Role of Immunotherapy in Hematological Malignancies”.

Hematological malignancies have been the target of immunotherapy since the advent of allogeneic stem cell transplantation, which has shown for the first time the pros and cons of boosting immune responses against tumor cells and the surrounding tissues. Allogeneic donor lymphocyte infusions have proven that it is possible to further boost allo-immune responses to re-attain remissions when the previous tumor immune surveillance has been somewhat lost. Moving from the experience with leukemias, tumor immunotherapy has recently been enriched with the introduction of different therapeutics that rely on potentiating and/or refueling immunity (checkpoint inhibitors, moAbs, and bispecific antibodies) up to the design of engineered T cells that are empowered to recognize tumor antigens through chimeric receptors (CAR-T). Indeed, hematological malignancies represent an ideal target for such approaches due to the direct access to the tumor bed by immune cells. However, a main limitation is represented by the tumor driven immune-suppressive microenvironment, which can turn off immune responses.

The aim of this Special Issue is to present the state-of-art in this field and to highlight the preclinical and clinical research strategies that are currently being explored to overcome the main limitations and improve the efficacy of immune-based treatments.         

Prof. Dr. Marco Rossi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor immunotherapy
  • bispecific antibodies
  • tumor microenvironment
  • CAR-T
  • hematological malignancies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 1375 KiB  
Review
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress
by Matteo Molica, Salvatore Perrone, Costanza Andriola and Marco Rossi
Cancers 2023, 15(20), 5060; https://doi.org/10.3390/cancers15205060 - 19 Oct 2023
Viewed by 1861
Abstract
In the last few years, molecularly targeted agents and immune-based treatments (ITs) have significantly changed the landscape of anti-cancer therapy. Indeed, ITs have been proven to be very effective when used against metastatic solid tumors, for which outcomes are extremely poor when using [...] Read more.
In the last few years, molecularly targeted agents and immune-based treatments (ITs) have significantly changed the landscape of anti-cancer therapy. Indeed, ITs have been proven to be very effective when used against metastatic solid tumors, for which outcomes are extremely poor when using standard approaches. Such a scenario has only been partially reproduced in hematologic malignancies. In the context of acute myeloid leukemia (AML), as innovative drugs are eagerly awaited in the relapsed/refractory setting, different ITs have been explored, but the results are still unsatisfactory. In this work, we will discuss the most important clinical studies to date that adopt ITs in AML, providing the basis to understand how this approach, although still in its infancy, may represent a promising therapeutic tool for the future treatment of AML patients. Full article
(This article belongs to the Special Issue The Role of Immunotherapy in Hematological Malignancies Volume II)
Show Figures

Figure 1

Back to TopTop